Merck KGaA is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.
The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.
At its 2016 Capital Market Day, the company provided an update on its objectives up to 2018. Beginning 2017, the company aims to gain approval of one medicine or new indication every year.
We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The company’s second-quarter 2017 earnings per American Depositary Receipt (ADR) came in at $1.06, compared to the year-ago figure of 80 cents.
Revenue: The company posted revenues of $4.3 billion in the reported quarter. The Healthcare and Life Science segment drove the company’s organic growth.
Key Stats: The company’s lead candidate, Bavencio’s label expansion in locally advanced or metastatic urothelial carcinoma was approved by the FDA in May. The drug’s marketing authorization application in EU as a monotherapy in adult mMCC patients also received a positive opinion from Committee for Medicinal Products for Human Use (CHMP) in July. The company’s multiple sclerosis candidate, Mavenclad, also received CHMP recommendation in June. Moreover, it announced an agreement, in April, to divest its biosimilars business to Fresenius, as part of the company’s strategy to focus on its pipeline of innovative medicines.
Guidance: For 2017, the company reduced its net sales forecast in the range of €15.3 billion – €15.7 billion (previously €15.5 billion – €16 billion). The company continues to expect a slight to moderate organic increase in sales. The company reiterated its earnings per share forecast in the range of €6.15 - €6.50.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential.
See these stocks now>>